Park Ha Biological Technology Co., Ltd.'s SEC filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries that sell Park Ha skincare and cosmetic products in China. Current reports on Form 6-K cover Nasdaq listing compliance, board changes, shareholder voting matters and amendments to its memorandum and articles.
The company's filings also describe its capital structure, including Class A ordinary shares, Class B ordinary shares with higher voting rights, warrants issued in public offerings, securities purchase agreements, placement agency arrangements and Form F-1 registration statement disclosures. These records connect financing activity and share-capital matters to BYAH's public-company governance and reporting obligations.
Park Ha Biological Technology Co., Ltd. filed Amendment No. 1 to its Form 20-F to expand risk, structural and financial disclosures in response to an SEC comment letter. The amendment enhances discussion of its Cayman holding company and PRC VIE structure, PRC regulatory, cybersecurity and HFCAA-related risks, and cash-transfer constraints within the group. It also revises MD&A to address fewer franchise contracts, share-based compensation and credit losses, and updates the audited financial statements and auditor’s report. As of October 31, 2025, the company had 296,488 Class A ordinary shares and 381,000 Class B ordinary shares issued and outstanding, and in August 2025 it transferred US$1.4 million from the Cayman parent to its WFOE subsidiary.
Park Ha Biological Technology Co., Ltd. filed a Form F-3 shelf registration to offer up to $300,000,000 of Class A ordinary shares and various securities, to be sold from time to time under prospectus supplements. The company warns of PRC regulatory, cybersecurity and HFCAA/PCAOB risks and discloses prior financings, corporate restructurings, and a January 28, 2026 follow-on unit offering.
Park Ha Biological Technology Co., Ltd. director Shan Yanan has filed an initial Form 3 insider ownership report. The available data shows no reported transactions or derivative positions, and no share holdings are detailed in this snapshot of the filing.
Park Ha Biological Technology Co., Ltd. CTO Li Xinyu has reported initial ownership on a Form 3. The filing shows 937.5 Class A Ordinary Shares are held indirectly through Changxin International Limited Partnership, where Ms. Li is a limited partner. A footnote states these shares were acquired on October 11, 2022.
Park Ha Biological Technology Co., Ltd. director Yu Xiaozhong filed an initial Form 3 to report insider status with respect to BYAH. The filing lists Yu as a director and confirms that, at the time of this report, no insider transactions or derivative positions are reported.
Park Ha Biological Technology Co., Ltd. filed an initial insider ownership report for CFO Zhu Xiaoyan. The filing shows 2,500 Class A Ordinary Shares held indirectly through Changxin International Limited Partnership. A footnote states these 2,500 Class A Ordinary Shares were acquired on October 11, 2022, with Ms. Zhu described as a limited partner of that partnership.
Park Ha Biological Technology Co., Ltd. director and CEO Zhang Xiaoqiu filed an initial Form 3 reporting her beneficial ownership in the company. She is identified as a director, officer and ten percent owner.
The filing shows indirect ownership of 381,000 Class B Ordinary Shares, held through Xiaoqiu Holdings Limited, where she is the sole shareholder and director. A footnote states that these 381,000 Class B Ordinary Shares were acquired on October 11, 2022, and the Form 3 records this existing position rather than reporting a new market transaction.
Park Ha Biological Technology Co., Ltd. director Sheng Qixiong has filed an initial statement of beneficial ownership as a reporting person. This Form 3 lists him as a director but shows no reported transactions, acquisitions, or derivative positions at the time of the filing.
Park Ha Biological Technology Co., Ltd. reported that Li Wang resigned as a director of the company, effective March 16, 2026. The company states that her resignation was not due to any disagreement with its operations, policies, or procedures.
The report is signed by Chief Executive Officer and Chairperson Xiaoqiu Zhang, indicating the change has been formally approved and acknowledged at the highest leadership level.
Park Ha Biological Technology Co., Ltd. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq notified the company that its Class A ordinary shares closed at or above $1.00 per share for 10 consecutive business days from February 20 through March 5, 2026.
Meeting this threshold satisfies Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, and Nasdaq has closed the matter. This removes the immediate risk that the company’s shares could be delisted for bid-price non-compliance.